Literature DB >> 18561375

Monitoring influenza virus content in vaccine production: precise assays for the quantitation of hemagglutination and neuraminidase activity.

Bernd Kalbfuss1, Anne Knöchlein, Tina Kröber, Udo Reichl.   

Abstract

Robust and precise quantitation of influenza virus is a premise for the efficient development of vaccine production processes. In this article, revised assays for the determination of hemagglutination (HA) and neuraminidase (NA) activity are presented. Bias of traditional discontinuous HA assays and operator dependency was overcome by introduction of a regression procedure. At little effort, a continuous assay result is obtained with repeatability as good as +29%/-22% in the best case (95% confidence intervals reported). Similarly, neuraminidase activity determined in microtiter plates resulted in repeatability better than +/-20%. NA activity decreased almost linearly for pH ranging from 5.8 to 7.8 and was enhanced by the addition of Ca2+. Non-linearity of the assay (due to unspecific adsorption) was overcome by addition of BSA. Using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid as substrate, Michaelis-Menten constants of 30 and 460 microM were determined for strains A/PR/8/34 (H1N1) and A/Equi 2/NM/1/93 (H3N8), respectively. The error introduced by approximation of Michaelis-Menten kinetics (zero and first order) was minimized by limiting substrate consumption to about 10%. Linearity of both assays was verified in dilution experiments. Applicability was demonstrated in three cases: virus propagation in mammalian cell culture, ultrafiltration and precipitation of nucleic acids.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18561375     DOI: 10.1016/j.biologicals.2007.10.002

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  29 in total

1.  Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.

Authors:  Lisa Walz; Sarah-Katharina Kays; Gert Zimmer; Veronika von Messling
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

Review 2.  Virus-like particles as antigenic nanomaterials for inducing protective immune responses in the lung.

Authors:  Agnieszka Rynda-Apple; Dustin P Patterson; Trevor Douglas
Journal:  Nanomedicine (Lond)       Date:  2014       Impact factor: 5.307

3.  Metabolic effects of influenza virus infection in cultured animal cells: Intra- and extracellular metabolite profiling.

Authors:  Joachim B Ritter; Aljoscha S Wahl; Susann Freund; Yvonne Genzel; Udo Reichl
Journal:  BMC Syst Biol       Date:  2010-05-13

4.  Quantitation of influenza virus using field flow fractionation and multi-angle light scattering for quantifying influenza A particles.

Authors:  Tatiana Bousse; David A Shore; Cynthia S Goldsmith; M Jaber Hossain; Yunho Jang; Charles T Davis; Ruben O Donis; James Stevens
Journal:  J Virol Methods       Date:  2013-07-31       Impact factor: 2.014

5.  Impact of host cell line adaptation on quasispecies composition and glycosylation of influenza A virus hemagglutinin.

Authors:  Jana Verena Roedig; Erdmann Rapp; Dirk Höper; Yvonne Genzel; Udo Reichl
Journal:  PLoS One       Date:  2011-12-07       Impact factor: 3.240

6.  Impact of different influenza cultivation conditions on HA N-Glycosylation.

Authors:  Jana V Roedig; Erdmann Rapp; Yvonne Genzel; Udo Reichl
Journal:  BMC Proc       Date:  2011-11-22

7.  Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells.

Authors:  Verena Lohr; Yvonne Genzel; Ingo Jordan; Dietmar Katinger; Stefan Mahr; Volker Sandig; Udo Reichl
Journal:  BMC Biotechnol       Date:  2012-10-30       Impact factor: 2.563

8.  Continuous influenza virus production in cell culture shows a periodic accumulation of defective interfering particles.

Authors:  Timo Frensing; Frank Stefan Heldt; Antje Pflugmacher; Ilona Behrendt; Ingo Jordan; Dietrich Flockerzi; Yvonne Genzel; Udo Reichl
Journal:  PLoS One       Date:  2013-09-05       Impact factor: 3.240

Review 9.  Analytical technologies for influenza virus-like particle candidate vaccines: challenges and emerging approaches.

Authors:  Christine M Thompson; Emma Petiot; Alexandre Lennaertz; Olivier Henry; Amine A Kamen
Journal:  Virol J       Date:  2013-05-04       Impact factor: 4.099

10.  Multiscale modeling of influenza A virus infection supports the development of direct-acting antivirals.

Authors:  Frank S Heldt; Timo Frensing; Antje Pflugmacher; Robin Gröpler; Britta Peschel; Udo Reichl
Journal:  PLoS Comput Biol       Date:  2013-11-21       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.